The SGLT-2i (empagliflozin) and GLP-1 RA (liraglutide and loxenatide) demonstrated beneficial effects on microbiota in patients with T2DM in terms of improving the colonies of Eubacterium, Roseburia, and Faecalibacterium and Firmicutes and Bacteroidetes, respectively, to the detriment of Escherichia-Shigella, Bilophila, Hungatella, and Acinetobacter baumannii in short-duration studies. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.